A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer

@inproceedings{Dickler2006AMP,
  title={A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Previously Treated Metastatic Breast Cancer},
  author={Maura N. Dickler},
  year={2006}
}

Topics from this paper.